Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).
J Clin Oncol
; 39(30): 3377-3390, 2021 10 20.
Article
in En
| MEDLINE
| ID: mdl-34115544
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Gene Amplification
/
Mutation Rate
/
Anaplastic Lymphoma Kinase
/
Neuroblastoma
Type of study:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Country/Region as subject:
Europa
Language:
En
Journal:
J Clin Oncol
Year:
2021
Document type:
Article
Affiliation country:
France
Country of publication:
United States